MedPath

Assessment of the responsiveness of the Rasch-built, CIPN-specific questionnaire (CIPN-RODS) to clinical changes in patients undergoing neurotoxic chemotherapy.

Completed
Conditions
chemotherapy-induced polyneuropathy
10027656
10034606
Registration Number
NL-OMON42804
Lead Sponsor
niversitair Medisch Centrum
Brief Summary

Trial is onging in other countries

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
5
Inclusion Criteria

1. Subjects must be candidates for chemotherapy including in the treatment plan platinum-based drugs or taxanes at doses expected to be potentially neurotoxic
2. Male and female subjects who are 18 years of age or older.
3. Subjects must give informed consent by signing and dating an informed consent form prior to study entry.
4. Subjects must have a Karnofsky performance score greater than or equal to 70.

Exclusion Criteria

1. Poor prognosis, with high probability to be unable to complete the planned chemotherapy treatment.
2. Concomitant neurologic conditions, e.g., brain tumor, spinal or brain metastases.
3. Severe depression that in the opinion of the Investigator would complicate the assessments.
4. Chronic treatment with antiepileptic drugs, antidepressants and major analgesics, unless stable dosing and conditions have been reached for 3 months prior to entry.
5. Subjects with a known presence of peripheral nerve damage due to another illness or medication.
6. Subjects who are currently receiving another medication that has known potential to produce neurologic peripheral nerve toxicity (e.g. metrodiazole or isoniazid).

Study & Design

Study Type
Observational invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath